Incyte Corp INCY:NASDAQ

Last Price$80.50NASDAQ Previous Close - Last Trade as of 4:00PM ET 1/17/20
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$78.96 (1)
Ask (Size)$82.10 (1)
Day Low / HighN/A - N/A
Volume1.4 M
 

View Biotechnology IndustryPeer Comparison as of 01/17/2020

 

Incyte Corp ( NASDAQ )

Price: $80.50
Change: -0.12 (0.15%)
Volume: 1.4 M
4:00PM ET 1/17/2020
 
 

Seattle Genetics Inc ( NASDAQ )

Price: $109.00
Change: +1.34 (1.24%)
Volume: 745.7 K
4:00PM ET 1/17/2020
 
 

Biomarin Pharmaceutical Inc ( NASDAQ )

Price: $88.27
Change: -0.86 (0.96%)
Volume: 1.7 M
4:00PM ET 1/17/2020
 
 

Alnylam Pharmaceuticals Inc ( NASDAQ )

Price: $118.82
Change: -0.52 (0.44%)
Volume: 860.4 K
4:00PM ET 1/17/2020
 
 

Exact Sciences Corp ( NASDAQ )

Price: $88.06
Change: -1.72 (1.92%)
Volume: 3.0 M
4:00PM ET 1/17/2020
 

Read more news Recent News

--Analyst Actions: JMP Securities Lifts Incyte's Price Target to $121 From $99, Maintains Market Outperform Rating
12:28PM ET 1/14/2020 MT Newswires

Price: 80.54, Change: +3.44, Percent Change: +4.46 ...

MorphoSys, Incyte Join Forces to Commercialize Blood Cancer Drug Tafasitamab in US
6:40AM ET 1/13/2020 MT Newswires

MorphoSys (MOR) and Incyte (INCY) said pre-market Monday that they have entered into an agreement for MorphoSys to license its therapeutic tafasitamab for...

Incyte Obtains European Medicines Agency's Validation of Marketing Application for Drug to Treat Bile Duct Cancer
3:52PM ET 1/07/2020 MT Newswires

Incyte (INCY) said Tuesday that the European Medicines Agency has validated the company's marketing authorization application for pemigatinib for the...

Insider Trends: Insider at Incyte Sells Shares for Tax Slowing 90-Day Buy Trend
4:32PM ET 1/03/2020 MT Newswires

Herve Hoppenot, Director and Chairman / CEO, reported a sale of 28,345 shares of Incyte (INCY) on Jan 02, 2020, for approximately $2,436,819 to satisfy tax...

View all Commentary and Analysis

Biotech Bonanza: 2020 Outlook In An Election Year
4:15PM ET 1/08/2020 Seeking Alpha

Incyte: Looking More Appealing, Yet Pipeline Conversion Is Required
12:09AM ET 1/06/2020 Seeking Alpha

Incyte Corporation: Wait And Watch
7:44AM ET 12/29/2019 Seeking Alpha

In Search Of The Best Growth Stocks
12:01PM ET 12/24/2019 Seeking Alpha

Company Profile

Business DescriptionIncyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE. View company web site for more details
Address1801 Augustine Cut-Off
Wilmington, Delaware 19803
Phone+1.302.498.6700
Number of Employees1,367
Recent SEC Filing01/17/20204
Chairman, President & Chief Executive OfficerHervé Hoppenot
Chief Financial Officer & Executive Vice PresidentChristiana Stamoulis
Chief Medical Officer & Executive Vice PresidentSteven H. Stein
Chief Scientific Officer & Executive VPDashyant Dhanak

Company Highlights

Price Open$80.98
Previous Close$80.62
52 Week Range$72.00 - 96.79
Market Capitalization$17.3 B
Shares Outstanding215.4 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement02/13/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings43.28
Earnings per Share$1.95
Beta vs. S&P 500N/A
Revenue$1.9 B
Net Profit Margin19.21%
Return on Equity18.66%

Analyst Ratings as of 01/02/2020

Buy
9
Overweight
0
Hold
10
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset